< Back to previous page
Researcher
Isabel Spriet
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Clinical Pharmacology and Pharmacotherapy (Division)
Member
From1 Jul 2013 → Today - Department of Pharmaceutical and Pharmacological Sciences (Department)
Member
From17 Nov 2003 → 30 Sep 2005
Projects
1 - 10 of 24
- Establishing personalized phage therapy and its comparative cost in difficult-to-treat infectionsFrom1 Jan 2025 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Development of a Triple Check-Point Antimicrobial Stewardship Intervention (TCP-AMSI) to ensure optimal initation, evaluation and de-escaltion of antimicrobial therapy in an Ethiopia tertiary care setting.From1 Sep 2024 → TodayFunding: BOF - doctoral mandates
- Leverage of a non-invasive clinical decision support tool for antibiotic allergy label delabeling and refinement beyond hospital use.From1 Oct 2023 → 30 Sep 2025Funding: IOF - technology validation in lab
- Non-invasive antibiotic allergy delabeling and refinement to optimize antimicrobial stewardshipFrom1 Oct 2023 → TodayFunding: FWO junior postdoctoral fellowship
- Assesment of the impact of a non-invasive clinical decision support tool for antibiotic allergy label delabeling and refinementFrom1 Oct 2023 → 30 Sep 2025Funding: FWO Applied Biomedical Research (TBM)
- Optimizing Antibacterial Dosing in Special Patient PopulationsFrom24 Jan 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- STRAtified Dosing based on Augmented renal clearance for CEFtriaxone in patients with severe community-acquired pneumonia: STRADA-CEF trial.From1 Oct 2022 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Advancing Pharmacist-Led Services for Optimised Pharmacotherapy Expanding the Check of Medication Appropriateness (CMA), Developing the Check of Compounding Appropriateness (CCA) & Establishing a Centre for Medicines Information (CMI)From1 Oct 2021 → 26 Sep 2025Funding: Own budget, for example: patrimony, inscription fees, gifts
- Clinical validation of antifungal dosing strategies in critically ill patientsFrom1 Oct 2021 → 30 Sep 2022Funding: BOF - postdoctoral mandates
- Exploration of the pharmacokinetics of clindamycin and its metabolites in special patients: from bioanalysis to clinical relevanceFrom1 Oct 2021 → 30 Sep 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 264
- Evaluation of the Allergy Fact Checker, a clinical decision support system for non-invasive beta-lactam delabeling: a mixed-methods study(2025)Published in: npj Digital MedicineISSN: 2398-6352Issue: 1Volume: 8
- A fluconazole population pharmacokinetics study to improve target attainment in critically ill patients(2025)Published in: INFECTIONISSN: 0300-8126
- Advancing Pharmacist-Led Services for Optimised Pharmacotherapy Expanding the Check of Medication Appropriateness (CMA), Developing the Check of Compounding Appropriateness (CCA) & Establishing a Centre for Medicines Information (CMI)(2025)
- The impact of the bedside check of medication appropriateness (BED-CMA) at the hematology ward: a mixed-methods study(2025)Published in: INTERNATIONAL JOURNAL OF CLINICAL PHARMACYISSN: 2210-7703Issue: 4Volume: 47
- Dose Optimization of Amikacin in the Emergency Department: A Population Pharmacokinetics Simulation Study(2025)Published in: THERAPEUTIC DRUG MONITORINGISSN: 0163-4356Issue: 3Volume: 47Pages: 353 - 362
- Anidulafungin exposure and population pharmacokinetics in critically ill patients with invasive candidiasis(2025)Published in: INFECTIONISSN: 0300-8126Issue: 3Volume: 53Pages: 1155 - 1165
- Continuous infusion of beta-lactam antibiotics in critically ill patients with sepsis: insights from daily clinical practice(2025)Published in: Intensive Care MedicineISSN: 0342-4642Issue: 4Volume: 51Pages: 827 - 828
- Outpatient parenteral antibiotic therapy in non-cystic fibrosis lung transplant recipients: characteristics, efficacy and safety ( Aug , 10.1007/ s 10096-024-04921-9 , 2024)(2025)Published in: European Journal of Clinical Microbiology & Infectious DiseasesISSN: 0934-9723
- Pharmacokinetics in Aging: Optimizing Drug Therapies for Geriatric Patients(2025)
- Review of the novel antifungal drug olorofim (F901318) (vol 24, 1256, 2024)(2024)Published in: BMC Infectious DiseasesISSN: 1471-2334Issue: 1Volume: 24
Linked dataset
1 - 1 of 1